Xvivo Perfusion ABXVIPF -1.32%91 Earnings per Share (Diluted) is $0.25 as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $41.71 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 665 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 51.43% on this metric.
Xvivo Perfusion AB's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.12.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25.
During the past 13 years, Xvivo Perfusion AB's highest 3-Year average EPS without NRI Growth Rate was 168.90% per year. The lowest was -42.60% per year. And the median was 17.40% per year.
Xvivo Perfusion AB (OTCPK:XVIPF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Xvivo Perfusion AB Earnings per Share (Diluted) Related Terms
Xvivo Perfusion AB Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Earnings per Share (Diluted) Chart
XVIPF vs ABT, SYK, MDT: Earnings per Share (Diluted) Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's PE Ratio falls into.
Xvivo Perfusion AB Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Xvivo Perfusion AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.25 mean?
Xvivo Perfusion AB (XVIPF) has a Earnings per Share (Diluted) of $0.25 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #323 out of 665 companies in the Medical Devices & Instruments industry, placing it in the top 48.6%.
Is Xvivo Perfusion AB's Earnings per Share (Diluted) too high?
Xvivo Perfusion AB's current Earnings per Share (Diluted) is $0.25. The Medical Devices & Instruments industry median Earnings per Share (Diluted) is 8.10. Xvivo Perfusion AB's value of $0.25 is 96.9% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #323 out of 665 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Earnings per Share (Diluted) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #323 out of 665 companies for Earnings per Share (Diluted). This puts Xvivo Perfusion AB in the upper half of its industry. The industry median Earnings per Share (Diluted) is 8.10. Xvivo Perfusion AB's value of $0.25 is 96.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.10, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Earnings per Share (Diluted) of $0.25 is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Earnings per Share (Diluted) is $0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.71, compared to a current price of $29.00 — trading 30.5% below its estimated fair value. The current Earnings per Share (Diluted) is $0.25 and 96.9% below the Medical Devices & Instruments industry median of 8.10. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Earnings per Share (Diluted) is $0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 30.5% below its estimated GF Value™ of $41.71.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Earnings per Share (Diluted): $0.25
GF Value™: $41.71 vs. price of $29.00 (30.5% below fair value)
Industry Position: 96.9% below the Medical Devices & Instruments median (#323 of 665)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
